Explain this page
Arphra AIPlain-English read on Patterson-UTI Energy, Inc.’s valuation06-11today
- TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer6d
- TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer6d
- Patterson-UTI (PTEN) is a Great Momentum Stock: Should You Buy?8d
- Is PattersonUTI Energy (PTEN) a Great Value Stock Right Now?38d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $12.43 (+23.80%)
Candlestick · 1Y
Open in chart workstation →PTEN
10.66+40.45%H 13.08L 7.21MA50 11.03MA200 —Avg vol 10.0M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.52% | -11.23% | -21.13% | -6.34% | +72.21% | +64.32% | +58.11% | -13.45% | -3.28% | -51.24% | +989.08% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$122.9K
1 txn
Net flow
−$122.9K
Aftermarket
LiveLast trade
$10.04
42 sh
Bid
$10.04
751 sh
Ask
$10.68
770 sh
Spread
$0.640
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Sector & industry today
LiveSectors
- Technology+2.51%
- Communication Services+1.85%
- Utilities+1.35%
- Consumer Cyclical+0.30%
- Consumer Defensive-0.30%
- Energy-0.45%
- Industrials-0.48%
- Basic Materials-0.66%
- Financial Services-0.67%
- Real Estate-0.99%
- Healthcare-1.51%
Top industries (issuer's industry highlighted)
- Oil & Gas Drilling-2.38%
- Oil & Gas Energy+8.53%
- Business Equipment & Supplies+5.82%
- Semiconductors+5.24%
- Electronic Gaming & Multimedia+5.23%
- Advertising Agencies-5.20%
- Medical - Equipment & Services+5.08%
- Grocery Stores-4.35%
- Financial - Mortgages+4.08%
- Broadcasting+4.00%
- Computer Hardware-3.67%
- Internet Content & Information+3.58%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancerbusinesswire.com·Jun 12, 2026
- TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancerbusinesswire.com·Jun 12, 2026
- Patterson-UTI (PTEN) is a Great Momentum Stock: Should You Buy?zacks.com·Jun 11, 2026
- Is PattersonUTI Energy (PTEN) a Great Value Stock Right Now?zacks.com·May 12, 2026
- Why This Fund’s $8 Million Patterson-UTI Bet Looks Like a Bullish Oil Recovery Tradefool.com·May 07, 2026
Recent analyst activity
DB- Jun 16, 2026PT$15.00Patterson-UTI Energy (PTEN) PT Raised to $15 at StifelStifel Nicolaus
- Jun 03, 2026PT$13.00Patterson-UTI price target lowered to $13 from $23 at Goldman SachsGoldman Sachs
Peers
No peer list available for PTEN.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Jaime Cesar director | Sell | 10,000 | $122.9K | May 05, 2026 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|